Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease characterized by profound fatigue, post-exertional malaise (PEM), and neurocognitive dysfunction. Immune dysregulation and gastrointestinal symptoms are commonly observed in ME/CFS patients. Despite affecting approximat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical medicine 2024-01, Vol.13 (1), p.275
Hauptverfasser: Rohrhofer, Johanna, Hauser, Lisa, Lettenmaier, Lisa, Lutz, Lena, Koidl, Larissa, Gentile, Salvatore Alessio, Ret, Davide, Stingl, Michael, Untersmayr, Eva
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page 275
container_title Journal of clinical medicine
container_volume 13
creator Rohrhofer, Johanna
Hauser, Lisa
Lettenmaier, Lisa
Lutz, Lena
Koidl, Larissa
Gentile, Salvatore Alessio
Ret, Davide
Stingl, Michael
Untersmayr, Eva
description Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease characterized by profound fatigue, post-exertional malaise (PEM), and neurocognitive dysfunction. Immune dysregulation and gastrointestinal symptoms are commonly observed in ME/CFS patients. Despite affecting approximately 0.89% of the general population, the underlying pathophysiological mechanisms remain poorly understood. This study aimed to elucidate the relationship between immunological characteristics and intestinal barrier function in ME/CFS patients. ME/CFS patients were stratified into two groups based on their immune competence. After documentation of detailed medical records, serum and plasma samples were collected for the assessment of inflammatory immune mediators and biomarkers for intestinal barrier integrity by ELISA. We found reduced complement protein C4a levels in immunodeficient ME/CFS patients suggesting a subgroup-specific innate immune dysregulation. ME/CFS patients without immunodeficiencies exhibit a mucosal barrier leakage, as indicated by elevated levels of Lipopolysaccharide-binding protein (LBP). Stratifying ME/CFS patients based on immune competence enabled the distinction of two subgroups with different pathophysiological patterns. The study highlights the importance of emphasizing precise patient stratification in ME/CFS, particularly in the context of defining suitable treatment strategies. Given the substantial health and socioeconomic burden associated with ME/CFS, urgent attention and research efforts are needed to define causative treatment approaches.
doi_str_mv 10.3390/jcm13010275
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10779792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A779345788</galeid><sourcerecordid>A779345788</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-7978d9651d092f96090cd8d396b22ea6233bb2a718dee76e0271f65067a896e03</originalsourceid><addsrcrecordid>eNpdkUtLAzEQgIMoKurJuyx4EaSaR3eTnERKfYCioF68hDSbbVOySU12hf57p_iq5pLHfHwzk0HokOAzxiQ-n5uWMEww5eUG2qWY8wFmgm2unXfQQc5zDEuIISV8G-0wQTGlgu6i19u27UP0ceqM9sWj7pwNXfHUJTg18Na5GAoXivul9sAU42DsYqZ9bJfWu87l89EsxQCRK2CnvS2elqFOsbX7aKvRPtuDr30PvVyNn0c3g7uH69vR5d3ADJnoBlxyUcuqJDWWtJEVltjUomaymlBqdUUZm0yo5kTU1vLKQqukqUpccS0kXNkeuvj0LvpJa2sD9Sft1SK5Vqelitqpv5HgZmoa3xWBH5JcUjCcfBlSfOtt7lTrsrHe62BjnxWVhA1LKE8AevwPncc-BehvRdEKhGX5S021t8qFJkJis5KqS8gJMi5WrtNPyqSYc7LNT80Eq9V01dp0gT5ab_OH_Z4l-wBYtp8M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2912679755</pqid></control><display><type>article</type><title>Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Rohrhofer, Johanna ; Hauser, Lisa ; Lettenmaier, Lisa ; Lutz, Lena ; Koidl, Larissa ; Gentile, Salvatore Alessio ; Ret, Davide ; Stingl, Michael ; Untersmayr, Eva</creator><creatorcontrib>Rohrhofer, Johanna ; Hauser, Lisa ; Lettenmaier, Lisa ; Lutz, Lena ; Koidl, Larissa ; Gentile, Salvatore Alessio ; Ret, Davide ; Stingl, Michael ; Untersmayr, Eva</creatorcontrib><description>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease characterized by profound fatigue, post-exertional malaise (PEM), and neurocognitive dysfunction. Immune dysregulation and gastrointestinal symptoms are commonly observed in ME/CFS patients. Despite affecting approximately 0.89% of the general population, the underlying pathophysiological mechanisms remain poorly understood. This study aimed to elucidate the relationship between immunological characteristics and intestinal barrier function in ME/CFS patients. ME/CFS patients were stratified into two groups based on their immune competence. After documentation of detailed medical records, serum and plasma samples were collected for the assessment of inflammatory immune mediators and biomarkers for intestinal barrier integrity by ELISA. We found reduced complement protein C4a levels in immunodeficient ME/CFS patients suggesting a subgroup-specific innate immune dysregulation. ME/CFS patients without immunodeficiencies exhibit a mucosal barrier leakage, as indicated by elevated levels of Lipopolysaccharide-binding protein (LBP). Stratifying ME/CFS patients based on immune competence enabled the distinction of two subgroups with different pathophysiological patterns. The study highlights the importance of emphasizing precise patient stratification in ME/CFS, particularly in the context of defining suitable treatment strategies. Given the substantial health and socioeconomic burden associated with ME/CFS, urgent attention and research efforts are needed to define causative treatment approaches.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm13010275</identifier><identifier>PMID: 38202282</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Chronic fatigue syndrome ; COVID-19 ; Development and progression ; Disease ; Encephalomyelitis ; Enzyme-linked immunosorbent assay ; Females ; Hypotheses ; Immunodeficiency ; Immunology ; Infections ; Irritable bowel syndrome ; Medical records ; Patients ; Protein binding ; Severe acute respiratory syndrome coronavirus 2 ; Tumor necrosis factor-TNF ; Viral infections</subject><ispartof>Journal of clinical medicine, 2024-01, Vol.13 (1), p.275</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-7978d9651d092f96090cd8d396b22ea6233bb2a718dee76e0271f65067a896e03</citedby><cites>FETCH-LOGICAL-c438t-7978d9651d092f96090cd8d396b22ea6233bb2a718dee76e0271f65067a896e03</cites><orcidid>0000-0002-2783-2099 ; 0000-0002-7461-0923 ; 0000-0002-1963-499X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10779792/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10779792/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38202282$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rohrhofer, Johanna</creatorcontrib><creatorcontrib>Hauser, Lisa</creatorcontrib><creatorcontrib>Lettenmaier, Lisa</creatorcontrib><creatorcontrib>Lutz, Lena</creatorcontrib><creatorcontrib>Koidl, Larissa</creatorcontrib><creatorcontrib>Gentile, Salvatore Alessio</creatorcontrib><creatorcontrib>Ret, Davide</creatorcontrib><creatorcontrib>Stingl, Michael</creatorcontrib><creatorcontrib>Untersmayr, Eva</creatorcontrib><title>Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease characterized by profound fatigue, post-exertional malaise (PEM), and neurocognitive dysfunction. Immune dysregulation and gastrointestinal symptoms are commonly observed in ME/CFS patients. Despite affecting approximately 0.89% of the general population, the underlying pathophysiological mechanisms remain poorly understood. This study aimed to elucidate the relationship between immunological characteristics and intestinal barrier function in ME/CFS patients. ME/CFS patients were stratified into two groups based on their immune competence. After documentation of detailed medical records, serum and plasma samples were collected for the assessment of inflammatory immune mediators and biomarkers for intestinal barrier integrity by ELISA. We found reduced complement protein C4a levels in immunodeficient ME/CFS patients suggesting a subgroup-specific innate immune dysregulation. ME/CFS patients without immunodeficiencies exhibit a mucosal barrier leakage, as indicated by elevated levels of Lipopolysaccharide-binding protein (LBP). Stratifying ME/CFS patients based on immune competence enabled the distinction of two subgroups with different pathophysiological patterns. The study highlights the importance of emphasizing precise patient stratification in ME/CFS, particularly in the context of defining suitable treatment strategies. Given the substantial health and socioeconomic burden associated with ME/CFS, urgent attention and research efforts are needed to define causative treatment approaches.</description><subject>Chronic fatigue syndrome</subject><subject>COVID-19</subject><subject>Development and progression</subject><subject>Disease</subject><subject>Encephalomyelitis</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Females</subject><subject>Hypotheses</subject><subject>Immunodeficiency</subject><subject>Immunology</subject><subject>Infections</subject><subject>Irritable bowel syndrome</subject><subject>Medical records</subject><subject>Patients</subject><subject>Protein binding</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Tumor necrosis factor-TNF</subject><subject>Viral infections</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkUtLAzEQgIMoKurJuyx4EaSaR3eTnERKfYCioF68hDSbbVOySU12hf57p_iq5pLHfHwzk0HokOAzxiQ-n5uWMEww5eUG2qWY8wFmgm2unXfQQc5zDEuIISV8G-0wQTGlgu6i19u27UP0ceqM9sWj7pwNXfHUJTg18Na5GAoXivul9sAU42DsYqZ9bJfWu87l89EsxQCRK2CnvS2elqFOsbX7aKvRPtuDr30PvVyNn0c3g7uH69vR5d3ADJnoBlxyUcuqJDWWtJEVltjUomaymlBqdUUZm0yo5kTU1vLKQqukqUpccS0kXNkeuvj0LvpJa2sD9Sft1SK5Vqelitqpv5HgZmoa3xWBH5JcUjCcfBlSfOtt7lTrsrHe62BjnxWVhA1LKE8AevwPncc-BehvRdEKhGX5S021t8qFJkJis5KqS8gJMi5WrtNPyqSYc7LNT80Eq9V01dp0gT5ab_OH_Z4l-wBYtp8M</recordid><startdate>20240103</startdate><enddate>20240103</enddate><creator>Rohrhofer, Johanna</creator><creator>Hauser, Lisa</creator><creator>Lettenmaier, Lisa</creator><creator>Lutz, Lena</creator><creator>Koidl, Larissa</creator><creator>Gentile, Salvatore Alessio</creator><creator>Ret, Davide</creator><creator>Stingl, Michael</creator><creator>Untersmayr, Eva</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2783-2099</orcidid><orcidid>https://orcid.org/0000-0002-7461-0923</orcidid><orcidid>https://orcid.org/0000-0002-1963-499X</orcidid></search><sort><creationdate>20240103</creationdate><title>Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</title><author>Rohrhofer, Johanna ; Hauser, Lisa ; Lettenmaier, Lisa ; Lutz, Lena ; Koidl, Larissa ; Gentile, Salvatore Alessio ; Ret, Davide ; Stingl, Michael ; Untersmayr, Eva</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-7978d9651d092f96090cd8d396b22ea6233bb2a718dee76e0271f65067a896e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Chronic fatigue syndrome</topic><topic>COVID-19</topic><topic>Development and progression</topic><topic>Disease</topic><topic>Encephalomyelitis</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Females</topic><topic>Hypotheses</topic><topic>Immunodeficiency</topic><topic>Immunology</topic><topic>Infections</topic><topic>Irritable bowel syndrome</topic><topic>Medical records</topic><topic>Patients</topic><topic>Protein binding</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Tumor necrosis factor-TNF</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rohrhofer, Johanna</creatorcontrib><creatorcontrib>Hauser, Lisa</creatorcontrib><creatorcontrib>Lettenmaier, Lisa</creatorcontrib><creatorcontrib>Lutz, Lena</creatorcontrib><creatorcontrib>Koidl, Larissa</creatorcontrib><creatorcontrib>Gentile, Salvatore Alessio</creatorcontrib><creatorcontrib>Ret, Davide</creatorcontrib><creatorcontrib>Stingl, Michael</creatorcontrib><creatorcontrib>Untersmayr, Eva</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rohrhofer, Johanna</au><au>Hauser, Lisa</au><au>Lettenmaier, Lisa</au><au>Lutz, Lena</au><au>Koidl, Larissa</au><au>Gentile, Salvatore Alessio</au><au>Ret, Davide</au><au>Stingl, Michael</au><au>Untersmayr, Eva</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2024-01-03</date><risdate>2024</risdate><volume>13</volume><issue>1</issue><spage>275</spage><pages>275-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease characterized by profound fatigue, post-exertional malaise (PEM), and neurocognitive dysfunction. Immune dysregulation and gastrointestinal symptoms are commonly observed in ME/CFS patients. Despite affecting approximately 0.89% of the general population, the underlying pathophysiological mechanisms remain poorly understood. This study aimed to elucidate the relationship between immunological characteristics and intestinal barrier function in ME/CFS patients. ME/CFS patients were stratified into two groups based on their immune competence. After documentation of detailed medical records, serum and plasma samples were collected for the assessment of inflammatory immune mediators and biomarkers for intestinal barrier integrity by ELISA. We found reduced complement protein C4a levels in immunodeficient ME/CFS patients suggesting a subgroup-specific innate immune dysregulation. ME/CFS patients without immunodeficiencies exhibit a mucosal barrier leakage, as indicated by elevated levels of Lipopolysaccharide-binding protein (LBP). Stratifying ME/CFS patients based on immune competence enabled the distinction of two subgroups with different pathophysiological patterns. The study highlights the importance of emphasizing precise patient stratification in ME/CFS, particularly in the context of defining suitable treatment strategies. Given the substantial health and socioeconomic burden associated with ME/CFS, urgent attention and research efforts are needed to define causative treatment approaches.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38202282</pmid><doi>10.3390/jcm13010275</doi><orcidid>https://orcid.org/0000-0002-2783-2099</orcidid><orcidid>https://orcid.org/0000-0002-7461-0923</orcidid><orcidid>https://orcid.org/0000-0002-1963-499X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2077-0383
ispartof Journal of clinical medicine, 2024-01, Vol.13 (1), p.275
issn 2077-0383
2077-0383
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10779792
source MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access
subjects Chronic fatigue syndrome
COVID-19
Development and progression
Disease
Encephalomyelitis
Enzyme-linked immunosorbent assay
Females
Hypotheses
Immunodeficiency
Immunology
Infections
Irritable bowel syndrome
Medical records
Patients
Protein binding
Severe acute respiratory syndrome coronavirus 2
Tumor necrosis factor-TNF
Viral infections
title Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T03%3A46%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunological%20Patient%20Stratification%20in%20Myalgic%20Encephalomyelitis/Chronic%20Fatigue%20Syndrome&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Rohrhofer,%20Johanna&rft.date=2024-01-03&rft.volume=13&rft.issue=1&rft.spage=275&rft.pages=275-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm13010275&rft_dat=%3Cgale_pubme%3EA779345788%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2912679755&rft_id=info:pmid/38202282&rft_galeid=A779345788&rfr_iscdi=true